Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Optimism over the new malaria vaccine being tested in Africa could be set to fall after results suggested its effect could reduce over time and that it disappears fastest in children who are most exposed to malarial mosquito bites.
Scientists point out that they will need to see the full results, from large-scale trials of thousands of children, before they really know how useful the vaccine ? developed by GlaxoSmithKline and known only as RTS,S ? will be.
But the tests follow a string of disappointing results, which have clearly shown how difficult it is to make a vaccine to protect against the disease, which kills more than 650,000 children, most of them very young, a year.
http://www.guardian.co.uk/society/2013/mar/20/malaria-vaccine-test-results-disappoint
Scientists point out that they will need to see the full results, from large-scale trials of thousands of children, before they really know how useful the vaccine ? developed by GlaxoSmithKline and known only as RTS,S ? will be.
But the tests follow a string of disappointing results, which have clearly shown how difficult it is to make a vaccine to protect against the disease, which kills more than 650,000 children, most of them very young, a year.
http://www.guardian.co.uk/society/2013/mar/20/malaria-vaccine-test-results-disappoint